Poor
Mostly Unaligned
Patient Risk:
Moderate
Summary
Most claims are not verifiable from the provided FDA label excerpts (which focus on indications, dosing/administration, contraindications, warnings, adverse reactions, and some population info). Several non-label claims relate to pricing, manufacturer, generics, patent/exclusivity, and patient assistance, none of which are supported or contradicted by the supplied label text.
Category Scores
Accurate Statements
Creon is a pancreatic enzyme replacement therapy (PERT) medication.
Supported indirectly by label description/mechanism: CREON is pancrelipase (mixture of enzymes) for exocrine pancreatic insufficiency (Sections 1 and 11). The term “PERT” is not used in the excerpts, but the concept aligns with indicated use and pancrelipase enzyme replacement.
Unsupported Statements
The cost of Creon can vary depending on dosage strength, number of capsules per prescription, insurance coverage, and pharmacy location.
No pricing/cost variability information appears in the provided label excerpts.
Creon is manufactured by AbbVie.
The provided label excerpts do not mention manufacturer/AbbVie.
As an exclusive brand, Creon’s prices are generally higher than generic alternatives.
No statements about brand exclusivity pricing or generics appear in the provided label excerpts.
Some pharmacies and patient assistance programs may offer price reductions or rebates for Creon.
No information about patient assistance programs, rebates, or pharmacy pricing appears in the provided label excerpts.
There are no FDA-approved generic equivalents available for Creon.
No FDA generic-equivalency/approval status information appears in the provided label excerpts.
There are similar medications with similar active ingredients that may be used as substitutes for Creon.
The provided label excerpts do not discuss substitutes or alternative drugs.
The average retail price of Creon 12,000 Units per 24 hours (60 capsules) is around $1,900.
No retail price figures are provided in the label excerpts.
Without insurance, the cash price of Creon may be significantly higher.
No insurance/cash pricing statements are provided in the label excerpts.
With insurance coverage, patients may have copays ranging from $20 to $50 per prescription.
No copay ranges appear in the provided label excerpts.
AbbVie’s patient assistance program may provide discounts or free medication to eligible patients.
No patient assistance or AbbVie program details appear in the provided label excerpts.
The patent for Creon expired in 2016.
No patent or exclusivity timelines appear in the provided label excerpts.
The exclusivity period on some brand-name products has expired, allowing for generic production to occur.
No exclusivity/patent/generic-production statements appear in the provided label excerpts.
Contradictions
Important Omissions
No dosage/administration safety details from the label were provided (e.g., dose-limiting units/kg/meal, instruction to swallow capsules whole, not to crush/chew, and monitoring/considerations tied to warnings such as fibrosing colonopathy and hyperuricemia).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response focuses largely on pricing/manufacturing/patent and substitution/general generic availability claims that are not supported by the provided FDA label excerpts. It does not include label-based dosing/administration safety instructions or warnings, which may be material for safe use. However, it does not directly state incorrect dosing instructions or contradict contraindications/warnings within the provided excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Unaligned
Primary Issue
Many claims (pricing, manufacturer, patient assistance, generic availability, patent/exclusivity timelines, substitution) are not supported by the supplied FDA label excerpts and therefore cannot be verified against the prescribing information.
Suggested Improvement
Limit claims to what is supported by the provided label excerpts (e.g., indication for exocrine pancreatic insufficiency and label-based dosing/administration/warnings). Remove or clearly qualify non-label topics (pricing, AbbVie programs, generic/patent/exclusivity status) unless supported by the actual label text provided.